KFAS
PTCT icon

Keating Financial Advisory Services’s PTC Therapeutics PTCT Stock Holding History

Keating Financial Advisory Services’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.87K Buy
72
+47
+188% +$3.39K ﹤0.01% 1470
2026
Q1 		$1.7K Sell
25
-4
-14% -$283 ﹤0.01% 1910
2025
Q4 		$2.2K Buy
+29
New +$2.11K ﹤0.01% 1551

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Keating Financial Advisory Services's PTCT Position: Q2 2026 in Review

Keating Financial Advisory Services increased its PTC Therapeutics (PTCT) stake by 188% in Q2 2026, buying an estimated $3.39K and bringing the position to 72 shares worth $5.87K. The position accounts for ﹤0.01% of the portfolio, ranked #1470.

Keating Financial Advisory Services first reported a position in PTCT in Q4 2025 and has held it in 3 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Keating Financial Advisory Services held 72 shares of PTC Therapeutics worth $5.87K as of Q2 2026.
  • Keating Financial Advisory Services bought 47 PTC Therapeutics shares in Q2 2026, an estimated $3.39K.
  • PTC Therapeutics made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #1470 holding.
  • Keating Financial Advisory Services first reported a position in PTC Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.